A Phase 1 interventional study of Romosozumab and Placebo in Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 45 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-31.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing romosozumab in Bone Diseases, Metabolic — none open to participants now, 1 under way, none of them phase 3. romosozumab · Bone Diseases, Metabolic.
Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, this one is the 9th largest by enrollment, is the only one that started in 2010, is one of 4 in phase 1, and was the 4th registered.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
Browse Bone Diseases, Metabolic studies →None of the 11 studies testing romosozumab in Bone Diseases, Metabolic is open now. The open studies under Bone Diseases, Metabolic, anywhere →
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 45 Years to 70 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2010.
This study's enrollment of 31 is below the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 74 across the 11 interventional studies. Of the 10 that completed or were terminated, 10 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Bone Diseases, Metabolic by Amgen: none open now, none under way, none of them phase 3. Of 23 finished, 21 (91%) have results posted.
Among the 23 studies in Bone Diseases, Metabolic by Amgen, this one is the 20th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 1, and was the 16th registered.
Amgen’s Bone Diseases, Metabolic studies by the year they started, since 2002.
1 of the studies testing romosozumab in Bone Diseases, Metabolic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 23 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese and non-Japanese women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.
Drug: Romosozumab
Participants will receive a single dose of placebo.
Drug: Placebo
Administered by subcutaneous injection
Also known as: AMG 785, EVENITY™
Administered by subcutaneous injection
Number of Participants With Adverse Events
A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.
Time frame: Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments.
Number of Participants Who Developed Anti-romosozumab Binding Antibodies
Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.
Time frame: Day 29, and end of study (day 57 for participants assigned to 1 or 3 mg/kg romosozumab/placebo or day 85 for participants assigned to 5 mg/kg romosozumab/placebo)
Serum Calcium Levels
Time frame: Baseline, days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Serum Intact Parathyroid Hormone (iPTH) Levels
Time frame: Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Time frame: Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)
Time frame: Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Percent Change From Baseline in Sclerostin
Time frame: Baseline and days 12, 29, 43, 57, 71, and 85
Time to Maximum Observed Concentration of Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Maximum Observed Concentration of Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Apparent Clearance (CL/F) of Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
This study was conducted at 2 study centers in the United States. Eligible participants were healthy, postmenopausal first, second, or third generation Japanese women and non-Japanese women residing in the United States.
| Milestone | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 | 2 | 4 |
| Received study drug | 6 | 6 | 6 | 6 | 2 | 4 |
| Completed | 6 | 6 | 6 | 6 | 2 | 4 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.
| Participants | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Any adverse event | 6 | 4 | 3 | 6 | 2 | 4 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-related adverse events | 2 | 1 | 2 | 1 | 0 | 0 |
| AEs leading to discontinuation of study drug | 0 | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.
| Participants | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants Who Developed Anti-romosozumab Binding Antibodies | 0 | 0 | 0 | 0 | 0 | 0 |
| mmol/L | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Baseline | 2.34 ± 0.04 | 2.31 ± 0.04 | 2.33 ± 0.03 | 2.38 ± 0.03 | 2.28 ± 0.08 | 2.45 ± 0.04 |
| Day 2 | 2.33 ± 0.04 | 2.34 ± 0.03 | 2.31 ± 0.03 | 2.36 ± 0.03 | 2.34 ± 0.04 | 2.40 ± 0.05 |
| Day 3 | 2.33 ± 0.05 | 2.36 ± 0.04 | 2.31 ± 0.03 | 2.38 ± 0.03 | 2.34 ± 0.01 | 2.43 ± 0.03 |
| Day 4 | 2.32 ± 0.05 | 2.31 ± 0.03 | 2.30 ± 0.03 | 2.32 ± 0.03 | 2.38 ± 0.02 | 2.36 ± 0.04 |
| Day 6 | 2.39 ± 0.05 | 2.30 ± 0.03 | 2.31 ± 0.04 | 2.35 ± 0.04 | 2.28 ± 0.02 | 2.40 ± 0.03 |
| Day 8 | 2.39 ± 0.05 | 2.25 ± 0.02 | 2.31 ± 0.03 | 2.29 ± 0.03 | 2.35 ± 0.00 | 2.38 ± 0.03 |
| Day 12 | 2.35 ± 0.06 | 2.27 ± 0.05 | 2.33 ± 0.03 | 2.28 ± 0.02 | 2.33 ± 0.03 | 2.28 ± 0.04 |
| Day 22 | 2.31 ± 0.03 | 2.31 ± 0.03 | 2.28 ± 0.05 | 2.25 ± 0.03 | 2.33 ± 0.00 | 2.36 ± 0.03 |
| Day 29 | 2.37 ± 0.03 | 2.30 ± 0.04 | 2.28 ± 0.03 | 2.30 ± 0.02 | 2.36 ± 0.04 | 2.38 ± 0.05 |
| Day 43 | 2.35 ± 0.04 | 2.33 ± 0.03 | 2.28 ± 0.03 | 2.34 ± 0.04 | 2.30 ± 0.07 | 2.34 ± 0.01 |
| Day 57 | 2.37 ± 0.03 | 2.32 ± 0.04 | 2.29 ± 0.04 | 2.30 ± 0.03 | 2.28 ± 0.00 | 2.31 ± 0.02 |
| Day 71 | 2.34 ± 0.01 | — | — | 2.39 ± 0.02 | — | — |
| Day 85 | 2.29 ± 0.01 | — | — | 2.35 ± 0.02 | — | — |
| pmol/L | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Baseline | 4.47 ± 0.97 | 4.24 ± 0.70 | 4.93 ± 0.84 | 3.63 ± 0.62 | 3.77 ± 1.65 | 2.73 ± 0.37 |
| Day 2 | 4.51 ± 0.78 | 4.92 ± 0.78 | 5.01 ± 0.47 | 4.23 ± 0.54 | 3.50 ± 1.49 | 2.57 ± 0.23 |
| Day 3 | 4.93 ± 0.71 | 4.69 ± 0.69 | 5.38 ± 0.44 | 4.58 ± 0.76 | 3.50 ± 1.06 | 2.89 ± 0.37 |
| Day 4 | 4.47 ± 0.84 | 5.09 ± 0.69 | 5.09 ± 0.23 | 5.20 ± 1.13 | 3.93 ± 1.70 | 3.55 ± 0.73 |
| Day 6 | 4.21 ± 0.67 | 4.97 ± 0.93 | 5.75 ± 0.72 | 4.44 ± 0.77 | 3.82 ± 1.49 | 3.66 ± 0.66 |
| Day 8 | 4.19 ± 0.95 | 5.91 ± 0.86 | 5.23 ± 0.68 | 4.79 ± 0.90 | 4.14 ± 1.91 | 3.98 ± 0.68 |
| Day 12 | 5.04 ± 0.95 | 6.42 ± 0.59 | 5.46 ± 0.41 | 5.80 ± 0.61 | 4.19 ± 1.86 | 4.46 ± 0.64 |
| Day 22 | 4.69 ± 0.74 | 5.57 ± 0.64 | 6.15 ± 0.56 | 7.09 ± 0.84 | 5.46 ± 2.71 | 4.62 ± 0.68 |
| Day 29 | 4.83 ± 0.99 | 5.02 ± 0.74 | 5.92 ± 0.68 | 6.14 ± 0.72 | 4.83 ± 2.81 | 4.43 ± 0.40 |
| Day 43 | 4.61 ± 0.89 | 6.03 ± 0.73 | 5.27 ± 0.32 | 5.61 ± 0.84 | 3.93 ± 1.27 | 3.53 ± 0.35 |
| Day 57 | 3.89 ± 0.84 | 4.90 ± 0.64 | 4.87 ± 0.39 | 4.86 ± 0.55 | 2.76 ± 0.85 | 2.68 ± 0.27 |
| Day 71 | 3.40 ± 0.85 | — | — | 4.10 ± 0.47 | — | — |
| Day 85 | 3.02 ± 0.80 | — | — | 3.82 ± 0.58 | — | — |
| percent change | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP) | 26.85 ± 6.39 | 59.23 ± 12.21 | 102.57 ± 18.26 | 196.37 ± 29.79 | 8.30 ± 1.78 | 164.44 ± 35.58 |
| percent change | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Maximum Percent Change From Baseline in Serum C-telopeptide (CTX) | -12.64 ± 1.40 | -16.19 ± 7.36 | -35.92 ± 1.94 | -39.17 ± 5.13 | -25.46 ± 8.52 | -43.32 ± 9.96 |
| percent change | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Day 12 | -3.78 ± 3.72 | 6639.01 ± 534.50 | 13749.61 ± 1091.63 | 17028.81 ± 1875.81 | -17.95 ± 6.38 | 14652.96 ± 1349.38 |
| Day 29 | 591.80 ± 596.47 | 1602.70 ± 231.77 | 7667.80 ± 675.45 | 12723.54 ± 2138.65 | -14.54 ± 1.78 | 9581.13 ± 1283.73 |
| Day 43 | -15.43 ± 11.39 | 467.07 ± 55.62 | 3384.02 ± 613.99 | 6844.74 ± 1730.04 | -9.35 ± 4.59 | 4487.33 ± 1771.30 |
| Day 57 | -17.89 ± 11.96 | 167.37 ± 28.33 | 911.23 ± 156.09 | 2836.61 ± 1109.97 | -0.41 ± 12.65 | 1826.83 ± 917.98 |
| Day 71 | -39.80 ± 3.87 | — | — | 997.02 ± 532.06 | — | — |
| Day 85 | -27.41 ± 2.02 | — | — | 415.38 ± 243.40 | — | — |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| days | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Time to Maximum Observed Concentration of Romosozumab | 5.0 (5.0 to 8.0) | 5.0 (3.0 to 12) | 5.0 (5.0 to 7.0) | 5.0 (5.0 to 7.0) |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| µg/mL | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Maximum Observed Concentration of Romosozumab | 4.06 ± 1.45 | 17.1 ± 4.7 | 33.8 ± 8.1 | 18.6 ± 1.1 |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| µg*day/mL | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab | 64.0 ± 27.0 | 344 ± 90 | 804 ± 320 | 412 ± 136 |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| µg*day/mL | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab | 64.7 ± 26.8 | 347 ± 90 | 806 ± 323 | 421 ± 147 |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| mL/day/kg | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Apparent Clearance (CL/F) of Romosozumab | 18.6 ± 10.0 | 9.27 ± 2.64 | 6.98 ± 2.35 | 7.91 ± 2.68 |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| days | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab | — | 15.1 ± NA | 16.2 ± 4.1 | 15.3 ± 6.2 |
Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.
| days | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|
| Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab | 5.82 ± 1.05 | 6.31 ± 1.14 | 7.19 ± 1.55 | 6.81 ± 2.69 |
Collected over Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Japanese Women: Placebo | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Japanese Women: Romosozumab 1 mg/kg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Japanese Women: Romosozumab 3 mg/kg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Japanese Women: Romosozumab 5 mg/kg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Non-Japanese Women: Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Non-Japanese Women: Romosozumab 3 mg/kg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg |
|---|---|---|---|---|---|---|
| Vessel puncture site haematomaGeneral disorders | 2/6 | 1/6 | 1/6 | 1/6 | 1/2 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/4 |
| Venomous stingInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/4 |
| HeadacheNervous system disorders | 1/6 | 2/6 | 1/6 | 3/6 | 0/2 | 1/4 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/4 |
| Injection site haematomaGeneral disorders | 0/6 | 0/6 | 2/6 | 1/6 | 0/2 | 0/4 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/4 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/4 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/4 |
| Transaminases increasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/4 |
All treated participants
| Age, Categorical(Participants) | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 5 | 6 | 3 | 2 | 4 | 24 |
| >=65 years | 2 | 1 | 0 | 3 | 0 | 0 | 6 |
| Age, Continuous(years) | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 60.8 ± 5.7 | 59.3 ± 4.9 | 61.7 ± 3.0 | 59.7 ± 7.7 | 57.5 ± 3.5 | 55.0 ± 4.8 | 59.5 ± 5.3 |
| Sex: Female, Male(Participants) | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 6 | 6 | 6 | 6 | 2 | 4 | 30 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Japanese Women: Placebo | Japanese Women: Romosozumab 1 mg/kg | Japanese Women: Romosozumab 3 mg/kg | Japanese Women: Romosozumab 5 mg/kg | Non-Japanese Women: Placebo | Non-Japanese Women: Romosozumab 3 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 6 | 1 | 0 | 25 |
| White | 0 | 0 | 0 | 0 | 1 | 4 | 5 |
No study locations are listed for this record.
Ran from May 2010 to primary completion in Nov 2010, 5 months.
Results were first posted in Jul 2019, 8 years 8 months after primary completion.
Of 13 phase 1 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 37. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab